Preclinical study of a new (177)Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells

OBJECTIVE(S): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Asia Ocean J Nucl Med Biol
Hlavní autoři: Behnammanesh, Hossein, Erfani, Mostafa, Hajiramezanali, Maliheh, Jokar, Safura, Geramifar, Parham, Sabzevari, Omid, Amini, Mohsen, Mazidi, Seyed Mohammad, Beiki, Davood
Médium: Artigo
Jazyk:Inglês
Vydáno: Mashhad University of Medical Sciences 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7354249/
https://ncbi.nlm.nih.gov/pubmed/32714998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/AOJNMB.2020.44432.1299
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky